Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Lipoprotein-associated coagulation inhibitor

Criteria

Inclusion Criteria:

• Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence

• Pneumonia of sufficient severity to require ICU admission and management

Exclusion Criteria:

• Pregnancy

• Weight over 150 kg

• Patients at increased risk of bleeding

• Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa

• Treatment with heparin or anticipated need for heparin